Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TOI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOncology Institute rebrands to Starling Oncology, changes ticker to STLN
Filed August 3, 2026 · Period ending July 28, 2026 · ~1 min read
Key Changes
-
high
Company has reached profitability, marking a turnaround milestone after several years of operational rebuilding and scaling its technology-enabled care model.
Exhibit 99.1 view on EDGAR → -
medium
Legal name changed from The Oncology Institute, Inc. to Starling Oncology, Inc. via Delaware certificate of amendment filed July 28, 2026, effective immediately.
Item 5.03 — Amendments to Articles of Incorporation or Bylaws verify on EDGAR → -
medium
Nasdaq ticker symbol changed from TOI to STLN effective August 3, 2026; CUSIP number remains unchanged at 68236X100, requiring no shareholder action.
Item 5.03 — Amendments to Articles of Incorporation or Bylaws verify on EDGAR → -
medium
Company serves approximately 2.1 million patients through more than 400 clinicians across more than 100 clinic locations in five states.
Exhibit 99.1 view on EDGAR →
Summary
The Oncology Institute completed a corporate rebrand to Starling Oncology on July 28, 2026, with its Nasdaq ticker changing from TOI to STLN effective August 3, 2026. The rebrand reflects the company's evolution into an integrated oncology platform and coincides with management's disclosure that the company has reached profitability after several years of operational rebuilding. This profitability milestone represents a significant turnaround for the value-based oncology provider.
The company disclosed its current operational scale: approximately 2.1 million patients served through more than 400 employed and network clinicians across more than 100 clinic locations in five states. Management emphasized that the rebrand involves no disruption to patient care or business operations. Shareholders need take no action; the CUSIP number remains unchanged and shares will automatically trade under the new ticker symbol.
Section-by-Section Diff
Event · Exhibit 99.1
Added in current filing · view on EDGAR →
The Oncology Institute, Inc. ("TOI" or “the Company”), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to “Starling Oncology, Inc.™.” The Company's common stock will begin trading under the new ticker symbol "STLN” on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol “TOI.”
The company has changed its name from The Oncology Institute to Starling Oncology and will trade under the new ticker symbol STLN starting August 4, 2026. The rebrand reflects the company's evolution into an integrated oncology platform and marks a milestone in its growth trajectory. Management emphasizes no disruption to patient care or business operations during the transition.
Added in current filing · view on EDGAR →
Starling Oncology offers cutting-edge, evidence-based cancer care to a population of approximately 2.1 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with leading oncology organizations. With more than 400 employed and network clinicians and more than 100 clinics and network locations across five states and growing
The company disclosed its current operational scale, serving approximately 2.1 million patients through more than 400 clinicians across more than 100 clinic locations in five states. This provides investors with context on the company's footprint and patient reach under the new brand identity.
Added in current filing · view on EDGAR →
We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model.
The CEO stated that the company has reached profitability, representing a significant operational milestone. This achievement is positioned alongside the rebrand as evidence of the company's successful turnaround and operational improvements over recent years.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 4, 2026 · How we verify